Montai Therapeutics

We're honored to be among the "Start-up of the Year" finalists as part of the upcoming 2024 @BiotechWeekBoston Awards. This recognition reflects our strong momentum over just a few years leveraging AI and untapped chemistry to discover breakthrough oral medicines for chronic diseases. We're looking forward to celebrating an incredible ecosystem of Boston-based innovators on September 23rd. #BiotechWeekBoston #BWBAwards https://lnkd.in/ehi_EvwZ

Exciting news! Flagship Pioneering has raised $3.6 billion to fuel breakthrough innovations that transform human health and sustainability. We are proud to be #FlagshipFounded as we pursue the use of advanced AI to mine novel chemistry and discover breakthrough oral solutions to some of today's most complex chronic diseases.

Montai CSO Lamya Shihabuddin is chairing the #PDDPSummit today in Boston. Together with leaders from across the drug discovery landscape, Lamya is sharing insights on how Montai is leveraging AI to create more precision and predictability in early #drugdiscovery. 

We're looking forward to connecting with colleagues and partners during #BIO2024 this week to share our development momentum and pursue new collaboration opportunities. If you’re attending and would like to meet, reach out to Christian Antoni or John Mayfield!

We are expanding our network of renowned scientific and technical advisors with the appointment of Larry Hamann to our Board of Directors and the formal launch of our Scientific Advisory Board (SAB). Read more on this accomplished group of thought leaders and their critical role in the Montai strategy. https://lnkd.in/er7pgDyb

Montai CEO Margo Georgiadis recently joined #TheHealthTechnologyPodcast hosted by the UCSF Rosenman Institute . Listen below for her reflections on her tech-to-biotech journey and on Montai's work to creatively apply the advanced computing power of AI to accelerate innovation in small molecule medicine. #healthcareinnovation #healthtech #techleaders 

Montai CEO Margo Georgiadis recently shared her perspective about the greatest opportunities for impact using AI in drug development as part of an interactive session hosted by Sano Genetics. She shares this and more insights during the webinar, linked below. #precisionmedicine https://lnkd.in/evebWsjM

Inside all of us – effectively hidden in plain sight - are molecules that we have consumed for millennia and we know influence our biology. AI is helping us find and connect these chemical building blocks to powerful disease pathways. See what our CEO Margo Georgiadis said in this WBUR article about the way we are applying AI to make bigger leaps in drug discovery. https://lnkd.in/eMXRnDrH

Innovation in the prevention and treatment of chronic disease took center stage at the #WuXiGlobalForum where our CEO Margo Georgiadis led a discussion with leaders from the American Heart Association, the American Cancer Society, and the American Diabetes Association. At Montai, we are leading the way toward a future where the discovery and development of new medicines happens with unprecedented speed and precision to the benefit of patients everywhere.

Our CEO Margo Georgiadis shared a stage with Anthony Costa of NVIDIA, Kathleen Sullivan of Microsoft Research and Marcello Damiani at Flagship Pioneering at #JPM24 for an insightful discussion on the power of generative AI in our industry. At Montai, we’ve built computational tools to “supercharge” our expert drug developers to find possibilities in untapped diverse chemistry and to drive unprecedented optionality and predictability in discovering and developing FIC small molecule medicines for complex biological pathways. Have a listen. https://lnkd.in/eZQBkGnZ